BRAF and non-small cell lung carcinoma: This multi-targeted approach allows sorafenib to inhibit both MAPK signaling driven by mutant BRAF and angiogenic pathways critical for tumor growth, offering a mechanistic rationale for its efficacy in BRAF non-V600E-mutant NSCLC [107,108].